Allen Silberstein’s Biotech Strategy

Allen Gabriel Silberstein’s fund, Silberstein Capital Management has a new Biotech Strategy. End Quote

New York, NY (1888PressRelease) November 16, 2022 - Allen Silberstein an investor in early-stage advanced start-ups, today announced he will finance game-changing innovations in medicine. Allen Silberstein is seeking iconoclastic founders aiming to reinvent today's broken healthcare system with radically better drugs, diagnostics, research tools, devices, and care delivery models. "This is perhaps the largest addressable market in the global economy, and we believe that the Mark Zuckerbergs and Larry Pages of healthcare are out there and will build generationally important companies that will transform medicine for decades to come.

Allen Silberstein is not interested in incremental improvements in healthcare," "Patients are waiting for innovations that will have great impact on their lives and we plan to be a catalyst to deliver these products."

Allen Silberstein will also focus on investing in companies engaged in the field of medical and pharmaceutical research with a particular interest in cancer-related medical research companies.

If you really looked to see where the advances in technology are being made, it's in the pharmaceutical and medical fields," says Allen Gabriel Silberstein.

Both private and government-backed firms have sunk tens of billions of dollars into research in the past decade. They are mapping out the entire human body and will know every gene and what it does as early as the end of next year. Pharmaceutical companies will be able to use that information to develop more powerful drugs.

Still, there already are plenty of funds trying to cash in on the same wave. Many were launched in the ill-fated biotech craze of the early 1990s. "Biotech was a brand new industry back then and it attracted a lot of attention," says Allen Silberstein "But people have kind of lost focus and didn't stay with it."

After an early boom in 1991, when the average biotech fund moved up 68.4%, the sector went bust a year later, when funds averaged a negative 6.7% return. Biotech rallied again in 1995, and funds rose an average 45%. Returns since then have been steady but below the broader market.

Some of the earlier funds have moved into investing in medical equipment and hospital supply firms, according to Allen Silberstein. He says the new focus will stick primarily to drugs and treatments that help to stifle and cure a variety of cancers. "They are a lot closer now than they were 10 years ago," Allen Silberstein says. "You are going to see products on the market that combat cancer within two years."

Unlike the money-losing firms that fill the Internet portfolio, Allen Silberstein says the medical investments will focus on firms with a solid bottom line. "We want companies that are going to be able to fund research and development without having to go outside for financing.

###

space

Other Related Press Releases